Novartis Kymriah receives EC approval for lymphoma treatment
Approval for Kymriah follows a positive CHMP opinion and is applicable to all 27 EU member states
Read Moreby John Pinching | May 4, 2022 | News | 0
Approval for Kymriah follows a positive CHMP opinion and is applicable to all 27 EU member states
Read Moreby Lucy Parsons | Aug 24, 2021 | News | 0
Phase III study was investigating treatment for B-cell non-Hodgkin lymphoma
Read Moreby Lucy Parsons | Aug 5, 2020 | News | 0
Company expect to file regulatory submissions in 2021
Read Moreby Anna Smith | Sep 11, 2019 | News | 0
MSD’s Keytruda, Pfizer’s Visimpro, AstraZeneca’s Forxiga and Shionogi’s Senshio were also accepted.
Read Moreby Selina McKee | Mar 11, 2019 | News | 0
Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scotland after cost-regulators rejected funding for the treatment in this setting.
Read Moreby Anna Smith | Feb 12, 2019 | News | 0
Gilead’s CAR-T therapy Yescarta has been rejected by the Scottish Medicines Consortium (SMC) for use on NHS Scotland, but Novartis’ Kymriah was given a green light.
Read Moreby Anna Smith | Feb 1, 2019 | News | 0
The National Institute for Health and Care Excellence (NICE) has approved Novartis’ chimeric antigen receptor T-cell (CAR T-cell) therapy Kymriah for treatment of adults with diffuse large B-cell lymphoma (DLBCL).
Read Moreby Selina McKee | Dec 3, 2018 | News | 0
Novartis has released longer-term analyses of data from the ELIANA and JULIET trials showing that its CAR-T cell therapy Kymriah demonstrated “strong efficacy” and “durable responses” in certain blood cancer patients.
Read Moreby Selina McKee | Nov 27, 2018 | News | 0
The first children to receive Novartis’ Kymriah – a ‘game-changing’ CAR-T therapy for cancer – will start treatment at Great Ormond Street Hospital in London this week, NHS England has announced.
Read Moreby Selina McKee | Nov 16, 2018 | News | 0
NICE has recommended a pioneering cancer treatment for people under the age of 25 with leukaemia in final draft guidelines.
Read Moreby Selina McKee | Sep 19, 2018 | News | 0
The National Institute for Health and Care Excellence has turned down NHS funding for use of Novartis’ CAR-T therapy Kymriah in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Read Moreby Selina McKee | Sep 5, 2018 | News | 0
Hospitals are gearing up to offer Novartis’ ground-breaking CAR-T therapy Kymriah to children with advanced leukaemia, after the drugmaker reached a deal with NHS England over its provision.
Read More




PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
